In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Exelixis, with a price target of $45.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback